Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives

被引:9
作者
Bobrowicz, Malgorzata [1 ]
Zagozdzon, Radoslaw [2 ,3 ]
Domagala, Joanna [1 ,4 ]
Vasconcelos-Berg, Roberta [5 ]
Guenova, Emmanuella [6 ,7 ]
Winiarska, Magdalena [1 ]
机构
[1] Med Univ Warsaw, Dept Immunol, PL-02097 Warsaw, Poland
[2] Med Univ Warsaw, Dept Clin Immunol, PL-02006 Warsaw, Poland
[3] Med Univ Warsaw, Dept Immunol Transplantol & Internal Dis, PL-02006 Warsaw, Poland
[4] Postgrad Sch Mol Med, PL-02091 Warsaw, Poland
[5] Univ Basel, Univ Hosp Basel, Dept Dermatol, CH-4031 Basel, Switzerland
[6] Univ Zurich, Univ Hosp Zurich, Dept Dermatol, CH-8091 Zurich, Switzerland
[7] Univ Lausanne, Dept Dermatol, CH-1011 Lausanne, Switzerland
关键词
dermatooncology; immune checkpoints; immunotherapy; monoclonal antibodies; MERKEL CELL-CARCINOMA; IMMUNE CHECKPOINT INHIBITORS; PHASE-II TRIAL; METASTATIC MELANOMA; PD-1; BLOCKADE; T-CELLS; BRENTUXIMAB VEDOTIN; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; ACQUIRED-RESISTANCE;
D O I
10.3390/cancers11101420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal antibodies (mAbs) targeting specific proteins are currently the most popular form of immunotherapy used in the treatment of cancer and other non-malignant diseases. Since the first approval of anti-CD20 mAb rituximab in 1997 for the treatment of B-cell malignancies, the market is continuously booming and the clinically used mAbs have undergone a remarkable evolution. Novel molecular targets are constantly emerging and the development of genetic engineering have facilitated the introduction of modified mAbs with improved safety and increased capabilities to activate the effector mechanisms of the immune system. Next to their remarkable success in hematooncology, mAbs have also an already established role in the treatment of solid malignancies. The recent development of mAbs targeting the immune checkpoints has opened new avenues for the use of this form of immunotherapy, also in the immune-rich milieu of the skin. In this review we aim at presenting a comprehensive view of mAbs' application in the modern treatment of skin cancer. We present the characteristics and efficacy of mAbs currently used in dermatooncology and summarize the recent clinical trials in the field. We discuss the side effects and strategies for their managing.
引用
收藏
页数:33
相关论文
共 282 条
[1]   Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers [J].
Afanasiev, Olga K. ;
Yelistratova, Lola ;
Miller, Natalie ;
Nagase, Kotaro ;
Paulson, Kelly ;
Iyer, Jayasri G. ;
Ibrani, Dafina ;
Koelle, David M. ;
Nghiem, Paul .
CLINICAL CANCER RESEARCH, 2013, 19 (19) :5351-5360
[2]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[3]  
[Anonymous], 2016, BLOOD
[4]  
[Anonymous], 2016, BLOOD
[5]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[6]   Brentuximab vedotin [J].
Ansell, Stephen M. .
BLOOD, 2014, 124 (22) :3197-3200
[7]   Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells [J].
Ansell, Stephen M. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (01) :99-105
[8]   Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sezary syndrome [J].
Anzengruber, Florian ;
Ignatova, Desislava ;
Schlaepfer, Tanja ;
Chang, Yun-Tsan ;
French, Lars E. ;
Pascolo, Steve ;
Contassot, Emmanuel ;
Bobrowicz, Malgorzata ;
Hoetzenecker, Wolfram ;
Guenova, Emmanuella .
LEUKEMIA & LYMPHOMA, 2019, 60 (08) :1899-1907
[9]   MCV and Merkel cell carcinoma: a molecular success story [J].
Arora, Reety ;
Chang, Yuan ;
Moore, Patrick S. .
CURRENT OPINION IN VIROLOGY, 2012, 2 (04) :489-498
[10]   Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. [J].
Ascierto, Paolo Antonio ;
Melero, Ignacio ;
Bhatia, Shailender ;
Bono, Petri ;
Sanborn, Rachel E. ;
Lipson, Evan J. ;
Callahan, Margaret K. ;
Gajewski, Thomas ;
Gomez-Roca, Carlos A. ;
Hodi, F. Stephen ;
Curigliano, Giuseppe ;
Nyakas, Marta ;
Preusser, Matthias ;
Koguchi, Yoshinobu ;
Maurer, Matthew ;
Clynes, Raphael ;
Mitra, Priyam ;
Suryawanshi, Satyendra ;
Munoz-Couselo, Eva .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35